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ABSTRACT 
IMMOBILIZATION OF RHODOCOCCUS ERYTHROPOLIS AS A POTENTIAL 
TREATMENT FOR ATHEROSCLEROSIS 
 
by Srikanth Vivek Darbha 
Cardiovascular disease is the leading cause of death in the United States and is 
primarily due to hypercholesterolemia.  The novel approach of combatting 
atherosclerosis presented in this research entails delivery of microencapsulated 
Rhodococcus erythropolis immobilized in biodegradable alginate-based microcapsules 
and utilizing the bacterium’s cholesterol oxidase enzyme pathway to degrade cholesterol 
from intermediate-stage arterial plaque.  The bacterial growth medium was optimized 
using Taguchi design methods to enable growth characterizations hindered by 
biosurfactant by-product.  Methodologies for extraction and quantification of 
biosurfactant and cholesterol were developed and conducted simultaneous to bacterial 
growth assessment.  Bacteria were encapsulated using atomization (850±50 µm) and 
inkjet bioprinting (32±5 µm) to study the effects of cell density and capsule 
miniaturization on the rate of cholesterol degradation.  The cholesterol degradation rate 
was determined to be independent of cell density, and capsule miniaturization led to a 
near 4-fold increase in cholesterol degradation, thus allowing for 61.8% cholesterol in an 
intermediate-stage lesion to be degraded.  
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1.0 INTRODUCTION!
1.1 Background 
Atherosclerosis is considered to be an inflammatory condition of the artery and is 
characterized by the narrowing due to buildup of a substance known as plaque.  It is one 
of the leading causes of death for men and women in the United States (Moses, 2007; 
Fontos, 2006; Sutton, 2005; Arjomand, 2003; Jenkins, 2002; Bitl, 1995; Serruys, 1994), 
and a wide variety of common ailments are associated directly with it, including 
cardiovascular disease (CVD), coronary heart disease (CHD), hyperlipidemia, and 
hypercholesterolemia.  
 Hyperlipidemia is the leading cause of cardiac illness and death (Rosamund, 
1998; Murray, 1997), specifically CHD, ischemic cerebrovascular disease, and peripheral 
vascular disease (Jain, 2007).  It had been established in 1984 that cholesterol was 
directly linked to CHD (McGill, 1968) such that a 1% drop in blood cholesterol levels led 
to a 2-3% reduced risk for CHD (AHA, 2001).  This is a significant statistic because 
CHD accounts for twice as many cancer-related deaths and ten times as many accident-
related deaths (McGill, 1968).  According to the World Health Organization (WHO), 
high cholesterol levels accounted for over 60% of CHD cases (Yusuf, 2004).  Cholesterol 
is also known to lead to damage in endothelial (arterial) tissue (McGill, 1968).  This was 
apparent in Europe where 45% of heart attacks in Western Europe and 35% in Central 
and Eastern Europe were due to high cholesterol (Yusuf, 2004). 
 Along with CHD and hypercholesterolemia, CVD assumes a large portion of the 
cardiovascular market. Some major risk factors for CVD include health conditions of 
! &!
large markets, including diabetes and hypertension, for example (George, 2010).  In 
2002, over 62 million patients suffered from CVD in the U.S. alone, and the total costs of 
treatment amounted to over $110 billion (du Souich, 2004).  It has been projected that by 
year 2030, CVD will remain the leading cause of death in the world (WHO, 2009).  In 
Europe especially, CVD takes its toll with over 4 million deaths per year, 38% of which 
occur in the UK (WHO, 2009).  
 One must also consider the corresponding market of cardiovascular stents, in 
particular the drug-eluting stents (DES).  In 2005, it was estimated that DESs constituted 
a market of approximately $5 billion (Congress, 2010).  In 2006, DESs accounted for 
over 70% of the stent market in the U.S. and 40% in Europe (Ong, 2006).  In 2009, 
approximately 80% of stents in the U.S. were of the DES subset (Maisel, 2007), and 
healthcare spending amounted to over $400 billion in the U.S. (Mensah, 2007).  It is 
projected that the market for DESs will amount to over $6 billion annually in the U.S. 
(Bischof, 2009).  
1.2 Physiology of Atherosclerotic Plaque 
Plaque is composed of cholesterol-filled macrophages, smooth muscle cells 
(SMC), glycosaminoglycans (GAG), collagen, fibrin, and cholesterol (Ross, 1976).  What 
causes atherosclerosis to progress is the formation of an atherosclerotic lesion, which 
occurs when low-density lipoprotein (LDL) breaches the damaged intima of the blood 
vessel (Brown, 1983).  The LDL is then oxidized, which causes the release of adhesion 
factors and chemotactic molecules (Moubayed, 2007).  These adhesions molecules in 
turn allow for freely flowing blood monocytes to adhere and bind to the endothelial layer 
! '!
of the vessel wall (Moubayed, 2007).  Specifically, the monocytes appear at the intima 
and subintima of the vessel wall (Imhof, 2004; Ley, 2007).  
Blood monocytes are an unbound species naturally present in blood and circulate 
to regions of inflammation in order to produce cytokines (Woollard, 2010).  They are also 
capable of differentiating into macrophages and even foam cells (Tacke, 2006; Varol, 
2009) they can consume oxidized LDL (Woollard, 2010) by way of receptor-mediated 
endocytosis (Goldstein, 1979; Basu, 1979; Goldstein, 1980; Goldstein, 1981). Next, is 
that the monocytes/macrophages consume oxidized LDL (Greaves, 2009) and then 
differentiate into foam cells, so named due to their foamy appearance similar to soapy 
lather.  It is the cholesterol that is stored as cholesteryl ester droplets within the 
macrophages/monocytes that contributes to the foamy appearance (Greaves, 2009).  Also, 
the cholesterol that is endocytosed undergoes a continuous cycle of hydrolysis and re-
esterification by various lysosomal enzymes (Brown, 1980).  The accumulation of these 
foam cells, also known as fatty streaks, is the early stage of plaque that is incorporated in 
the intima layer of the vessel (Galkina, 2009).  It is important to note that fatty streaks 
usually develop in those regions that have arterial branching (Hahn, 2009). 
The fatty streaks then accumulate and mature into a plaque core that is eventually 
surrounded by a cap of smooth muscle cells and a collagen cellular matrix (Woollard, 
2010).  During this time, a plethora of inflammatory cytokines and growth factors is 
secreted and furthers the progression of the plaque, which can eventually lead to 
thrombosis and even stenosis (Woollard, 2010).  Consequently, the plaque core becomes 
necrotic and can cause new blood vessels to form (Woollard, 2010).  The cap surrounding 
! (!
the plaque is capable of breaking off in the form of debris, thereby leading to cascades of 
coagulation and clotting (Fuster, 2005).  
Atherosclerosis is categorized into six stages (HVIF, 2010), outlined below: 
• Stage I, is a normal healthy artery with no damage or blockages.  
• Stage II is characterized by the presence of fatty streaks that appear vertically thick in 
the vessel wall.  However, there are no apparent symptoms of atherosclerosis o or any 
obstructions.  
• As the fatty streaks accumulate, the vessel enters Stage III and an atheroma begins to 
develop, thereby interfering with normal blood flow.  
• Stage IV is characterized by plaque maturation and hardening in which case over 
50% of the vessel diameter is available for blood flow. This results in high blood 
pressure and heart rate for the suffering individual.  
• During Stage V, the plaque may be subject to cracking in which clots may adhere. 
This can contribute to a progressed blockage, thereby leading to a significantly 
reduced blood flow to the heart such that prolonged angina may develop.  
• Stage VI is the most advanced stage at which clots may potentially obstruct the entire 
vessel lumen diameter. 
1.3 Current Treatment Methods for Atherosclerosis 
1.3.1. Pharmaceutical!
The main conventional treatment for atherosclerosis includes synthetic substances 
that fall into a class of drugs known as statins, which function to lower cholesterol levels 
through the inhibition of an enzyme (HMG-CoA reductase) that is responsible for 
! )!
cholesterol production in the liver.  Although effective for atherosclerotic treatment, 
statins have been shown to lead to death or non-fatal myocardial infarction (Athyros, 
2009).  Patients who discontinue the use of statins are set up for more adverse coronary 
complications (Athyros, 2009), especially during any subsequent surgery (Schouten, 
2007).  Since patients must not consume oral medication after surgery and there are no 
intravenous forms of statins, the discontinuation of statins during the surgery may lead to 
postoperative troponin release, myocardial infarction, or cardiovascular death (Athyros, 
2009). 
Another method of treatment that has gained attention is EDTA chelation therapy, 
which is claimed to be effective for atherosclerotic plaque degradation (Ernst, 2000; 
Ernst, 1997; Lewin, 1997).  EDTA chelation therapy comprises a strong market to the 
extent that out-of-pocket costs range from $400 million to $3 billion annually in the U.S. 
(Knudston, 2002; Lamas, 2000). 
1.3.2 Cardiovascular Stents  
Apart from pharmaceutical treatment, cardiovascular stents are being used in 
order to widen arterial lumen and thus allow blood flow to be unhindered.  Stents are 
typically placed into the coronary artery by way of a catheter and guide wire and then 
deployed during angioplasty.  The various types of stents that exist today are the result of 
an evolutionary transformation from traditional bare metal stents, to polymer stents, to 
the highly studied bioabsorbable stents that are gaining attention for their reduced risk of 
restenosis (Camenzind, 2007; Pfisterer, 2006; Tsimikas, 2006), which is the re-narrowing 
of an artery after it has been unblocked.  
! *!
According to Rajagopal, et al, two possible mechanisms have been hypothesized 
for the invocation of the restenosis phenomenon: arterial modeling and neointimal 
hyperplasia (Rajagopal, 2003).  There are two proposed types of arterial modeling that 
exist: positive and negative.  Positive remodeling involves enlargement of the coronary 
artery in response to plaque formation in order to limit luminal occlusion (Glagov, 1987).  
Negative remodeling involves further luminal occlusion in response to plaque buildup, 
thus contributing to restenosis (Rajagopal, 2003).  Neointimal hyperplasia involves a 
cellular cascade that ultimately results in proliferation of smooth muscle cells upon 
plaque rupture by way of balloon inflation from angioplasty (Pakala, 1997; Dorn II, 
1997).  
It has been shown that bare metal stents have led to significantly increased risk for 
restenosis (Tsimikas, 2006; Pakala, 1997; Dorn II, 1997), thereby requiring the use of 
dual antiplatelet therapy for prevention of restenosis.  Such therapy can lead to long-term 
bleeding, and the efficacy of it is still unproven (Doyle, 2009).  Hence, polymer stents 
were developed, but have been shown to lead to late thrombosis and are associated with 
diminished arterial healing, which is associated with delayed re-endothelialization and 
the continued presence of fibrin (Pfisterer, 2006; Joner, 2006; John, 2008).  Drug-eluting 
polymer stents were then developed to combat restenosis, but have been shown to be 
associated with inflammatory cell infiltration and possibly even arterial drug 
sequestration (Virmani, 2004; Carter, 2004; Finn, 2005), which may lead to arterial 
toxicity (Hoye, 2006; Kuchulakanti, 2006; Takano, 2006).  Hence, increases in drug 
concentration may be counterproductive for restenosis treatment.  It has been shown that 
! +!
luminal caliber significantly decreases after 6-8 months of drug-eluting polymer stent 
implantation and is due to the continued inflammatory response in the arterial wall 
(Byrne, 2009), which may be a result of residual polymer in the artery (Joner, 2006; 
Virmani, 2004; Finn, 2007).  
In order to avoid issues with metallic and polymer stents, bioabsorbable stents are 
being studied.  One such popular stent on the market is the EXCEL Sirolimus eluting 
stent, which is made of poly-lactic acid and degrades into CO2 and H2O by-products 
(Doyle, 2009).  EXCEL is associated with 5.4% restenosis and elicits no myocardial 
infarction, thrombosis, or death, thereby proving its initial safety and efficacy (Doyle, 
2009).  
 Since pharmaceutical treatments for atherosclerosis are very expensive and can 
lead to complications that may be fatal in nature, there is an imperative need to research 
and develop alternative treatment methods that are safe, effective, and inexpensive.  One 
such alternative that is gaining much attention is the concept of cell encapsulation, which 
is the central aim of this research effort.  Advantages of encapsulation include the 
presence of a biocompatible immunoisolation barrier for cell encapsulation, ensuring that 
the cells do not come into contact with blood (DeVos, 1997).   
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2.0 LITERATURE REVIEW!
2.1 Cholesterol-Degrading Bacteria 
 
Various strains of bacteria can degrade cholesterol through enzymatic pathways 
(ATCC, 2010).  Shown in Table 1 is a tabulated list of such bacteria as identified by the 
American Type Culture Collection (ATCC).  
Table 1. Bacteria information and availability (ATCC, 2010).  
 
ATCC No. Biosafety 
Level 
ATCC Medium 
# 
Temperature of Growth (°C) 
43121 1 416 34 
4277 1 196 26 
14811 1 196 26 
17825 1 3 26 
25544 1 3 26 
31216 1 44 26 
*31384 1 1374 30 
*31385 1 1374 30 
*31455 1 1374 30 
*31456 1 1374 30 
*31457 1 1374 30 
*31458 1 1374 30 
*31459 1 1374 30 
*31460 1 1374 30 
**35215 1 1317 30 
51222 1 1872 37 
BAA-148 1 1872 37 
 
The ATCC numbers with one asterisk correspond to those bacteria that grow on 
cholesterol media; the number with two asterisks corresponds to the bacterium that 
degrades cholesterol.  The bacterium of interest (in bold) in this study was ATCC 25544, 
also known as Rhodococcus erythropolis.  This species has the ability to produce 
biosurfactant compounds that are directly dependent upon the growth medium.  A 
! -!
glycolipid compound known as trehalose lipid (shown in Fig. 1) is produced by R. 
erythropolis when grown on a hydrocarbon medium (Franzetti, 2010). 
 
 
Figure 1. Chemical structure of Rhodococcus sp. trehalose lipid.!
Glycolipids are sugar molecules (mono or disaccharides) attached to fatty acids.  
The sugar moiety is polar, whereas the lipid moiety is non-polar, thus rendering it 
amphipathic.  Glycolipids produced by R. erythropolis decrease the surface tension and 
interfacial tensions of culture broth to 25-40 mN/m and 1-5 mN/m, respectively (Li, 
1984; Rapp, 1979; Kretschmer, 1982).  Several hypotheses have been formulated to 
explain this phenomenon: (i) the biosurfactant may aid in survival, (ii) the biosurfactant 
may aid in transport of nutrient, (iii) the biosurfactant may lead to reduced 
hydrophobicity of the culture broth (Franzetti, 2010).  
This particular strain produces the enzyme cholesterol oxidase that specifically 
degrades cholesterol (Eqn. 1) and has a molecular mass of approximately 55 kDa (Sojo, 
!" 
! 
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1997).  Cholesterol oxidase, 3!-Hydroxysteroid:oxygen oxidoreductase, is an enzyme 
that catalyzes the oxidation of cholesterol into cholest-4-en-3-one (Kreit, 2009). !!!"#$%#&!" ! !! !!!"#$%#&!"! "#$%&' !!!! ! !! !!!"#$%#! ! !! !"# (1) 
Although H2O2 is a known cytotoxic chemical, it is naturally decomposed by 
peroxisomes of the human body and can be cleared by the enzyme catalase (Eqn. 2). !!!!! !"#"$"%& !!!! ! !! (2) 
Cholesterol oxidase is derived from several microbial sources, including 
Arthrobacter (Wilmanska, 1988), Corynebacterium (Shirokane, 1977), R. erythropolis 
(Richmond, 1973; Atrat, 1992), Nocardia rhodochrous and Rhodococcus rhodochrous 
(Buckland, 1976; Aihara, 1986; Cheetham, 1980; Cheetham, 1982; Cheetham, 1979; 
Minuth, 1995), Mycobacterium (Schatz, 1949; Smith, 1995), Pseudomonas (Rhee, 1991), 
Schizopyllum commune (Fukuyama, 1979), Brevibacterium sterolicum (Uwajima, 1973; 
Ohta, 1991), Streptoverticillium cholesterolicum (Inouye, 1982), Streptomyces violascens 
(Ishizaki, 1989; Lartillot, 1990; Kamei, 1978), and Rhodococcus sp. (Watanabe, 1986; 
Kreit, 1992; Watanabe, 1989).  The enzyme’s activity is optimal at a pH of 7.0 and 37°C. 
Other physical properties vary from species to species.  Sojo, et al report that the ATCC 
25544 strain produces both intracellular (cell-bound) and extracellular cholesterol 
oxidase, but more intracellular cholesterol oxidase is produced than extracellular 
cholesterol oxidase (Sojo, 1997). 
Applications of cholesterol oxidase have been mainly geared towards cholesterol 
quantification through use as an analytical probe.  The utility of the enzyme is vast in 
application and has been studied with regards to cholesterol quantification of the 
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following: total and esterified serum (Kreit, 2009; Shirokane, 1977; Allain, 1974; Brooks, 
1983; Murata, 1992; Lapinleimu, 1994; Gray, 1995); LDL (Sugiuchi, 1998) and HDL 
(Cobbaert, 1998); cholesterol on the erythrocyte cell membranes (Lange, 1984); gall 
stones (Wei, 1989); human bile (Aufenanger, 1989; Bocos, 1992); fluorescence (Gray, 
1995) and chemiluminescence (Mike, 1992; Sasamoto, 1995) detection methods. 
Cholesterol oxidase has also been integrated into a rapid bioreactor to measure serum 
triglyceride and total cholesterol (Makino, 1987). 
Due to the diversity of the enzyme’s applications, many efforts have been 
expended on optimizing cholesterol oxidase production, which has been deemed as an 
expensive process due to low productivity.  Hence, efforts of cloning and genetic 
manipulation are of high interest to optimize production. 
2.1.1 Bacteria Growth Curve Theory!
 Shown in Fig. 2 is a standard bacteria growth curve.  There are four main phases, 
namely lag, log, stationary, and death/decline phases.  The lag phase occurs immediately 
after the bacteria culture is created.  During this phase, the bacteria cells are adapting to 
the new environment.  It is important to note that the cells are still active.  It is during this 
phase that the intracellular enzyme is produced (Shuler, 2002).  The log phase is the time 
during which the cells begin to actively replicate and grow at an exponential rate.  
Because nutrition is limited, there are a finite number of cells that can grow.  That is, the 
cells reach saturation at which point cell growth begins to cease.  The point at which the 
cell growth rate is equal to the cell death rate is when the population begins to stabilize 
and enters what is known as the stationary phase.  It is during this stationary phase that 
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extracellular enzyme is produced (Shuler, 2002).  The final phase for the cells is the 
death/decline phase, which is when the cell death rate exceeds the cell growth rate.  
 
 
Figure 2. Bacterial growth curve. 
2.2 Biocompatibility of Alginate 
Alginate is a polymer that is composed of "-L-guluronic acid (G) and !-D-
mannuronic acid (M) blocks (Nunamaker, 2007).  Depending on the ratio of these blocks, 
properties of the alginate material can be altered accordingly.  A higher percentage of G 
results in alginate that is stronger, while a higher percentage of M results in a more 
flexible gel (Amsden, 1999).  The range of flexibility changes according to the following 
order: MG > MM > GG (Smidsrod, 1973).  Part of the reason why higher G alginates are 
stronger is due to the greater number of cross-links that form as a result of the higher 
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affinity of Ca2+ for the G sites (Kong, 2004).  High G alginates are known to exhibit high 
permeability to antibodies (Klein, 1983; Stewart, 1993), which may potentially weaken 
its biocompatibility.  This increased biological response may be quelled through the use 
of alginate that consists of 40-45% G and is high purity (Fritschy, 1994; De Vos, 1997; 
De Vos, 1993; De Vos, 1994; De Vos, 1997). 
2.3 Microcapsule Technology 
2.3.1 Atomization 
Alginate microcapsules are used extensively because of the controllable range of 
membrane permeability and the ease of solvent free microcapsule synthesis steps 
conducted at the physiological pH of 7.4.  To immobilize enzyme bio-compound within 
alginate microcapsules, the compound at a specific concentration is suspended in medium 
viscosity sodium alginate and atomized into 10 % (w/v) CaCl2 cross-linking solution 
(Stewart, 1993).  The atomizer design (Fig. 3) is comprised of two concentric channels 
such that coaxial airflow shears the liquid droplets in a reproducible manner.  Droplet 
size can be controlled by adjusting the coaxial airflow rate (FA), the compound/Na-
alginate suspension flow rate (FL), and the radial dimensions of the atomizer.  
! %(!
  
 
Figure 3. Design of atomization needle (drawing not to scale).!
2.3.2 Inkjet Bioprinting 
 
Inkjet printing involves ejecting liquid droplets from a printhead (Fig. 4) by way 
of various modes of impulses, including acoustic, thermal, or piezoelectric (Martin, 2008; 
Le, 1998; Brunahl, 2002), which cause the pressure plate to oscillate back and forth, 
thereby releasing ink droplets.  The main advantages of inkjet printing include the 
miniaturization capability for droplet generation on the order of 10 µm (Dong, 2006) and 
method reproducibility.  The major disadvantages, however, are that this is a highly 
meticulous and time-consuming process, with regards to jetting biological fluids non-
Newtonian and highly viscous in nature (Dohnal, 2010).  

* *
1D$OJLQDWH  %LRFRPSRXQG )/
6WHULOH DLUIORZ )D
5HWUDFWDEOH 1R]]OH

! %)!
 
Figure 4. Cross-sectional view of inkjet printhead (drawing not to scale).!
2.4 Extraction Theory 
Extraction theory is based off of how a solute is distributed within a 2-phase 
system at equilibrium (Fournier, 2007).  Suppose that N1 moles of solute are (initially) 
mixed in N2 moles of aqueous liquid (phase II) and N3 moles of organic solvent (phase I), 
which has high selectivity for the solute.  Described in Eqn. 3 is the distribution of these 
three components amongst the two immiscible phases at equilibrium. 
 !!!!!!!!!!!!!! ! !!!!!!!!!!!!!!!!! (3) 
where !!! and !!!! are the activity coefficients of component i in phases I and II, 
respectively, !!!and !!!! are the mole fractions of component i in phases I and II, 
respectively, and !!!!!!!! and !!!! !!!  are the pure component fugacities of component 
i in phases I and II, respectively, as a function of temperature and pressure.  Since 
component i does not change state in either phase at the same temperature and pressure, 
the pure component fugacities of component i are the same in either phase.  Hence, Eqn. 
3 becomes: 
 !!!!!! ! !!!!!!!! (4) 
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where !!! and !!!! are the activity coefficients of component i in phases I and II, 
respectively, and !!!and !!!! are the mole fractions of component i in phases I and II, 
respectively.  Eqn. 4 can then be rearranged in order to obtain the partition coefficient K 
(Eqn. 5), which is the ratio of mole fractions of component i in either phase. 
 ! ! !!!!!!! ! !!!!!!! (5) 
where K is the partition coefficient, !!! and !!!! are the activity coefficients of component i 
in phases I and II, respectively, and !!!and !!!! are the mole fractions of component i in 
phases I and II, respectively. 
Shown in Fig.5 is the extraction scheme used in this research study.  
  
 
Figure 5. Cholesterol extraction scheme!
 
The partition coefficient, K, can be calculated as given in Eqn. 6. 
 ! ! !!"#!!!"#!!  (6) 
where ! is the partition coefficient, !!"#!  is the final mole fraction of solute in the 
organic phase, and !!"#!!  is the final mole fraction of solute remaining in the aqueous 
phase. 
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2.5 Prior Studies with Cholesterol-Degrading Bacteria 
Many strains of cholesterol-degrading bacteria strains have been identified and 
studied in the literature.  For this study, a literature survey was conducted on bacteria 
capable of producing cholesterol oxidase enzyme.  Shown in Table 2 is a summary of the 
literature survey of prior cholesterol degradation experiments.  Data of interest included 
those that pertained to microbial degradation of cholesterol as opposed to extraction of 
microbial-derived enzyme followed by cholesterol degradation. 
Johnson, et al (Johnson, 1990) studied cholesterol degradation by R. equi in BHI 
growth medium containing an initial cholesterol concentration of 125 µg/mL.  They 
reported that up to 80% of cholesterol was degraded over a 7-day period by 10 of 27 
cultures.  The same authors also studied cholesterol degradation in egg yolk and milk 
cream by R. equi. 33706.  It was reported that 40% of egg yolk cholesterol was degraded 
in 60 min, and 2.36% of milk cream cholesterol was removed in 60 min. 
Bianchi, et al (Bianchi, 1996) used bacteria strains ATCC 25544, ATCC 4277, 
and ATCC DSM20131 to compare cholesterol degradation rates for the cases of free and 
encapsulated bacteria in chitin.  Cell concentrations were taken from the exponential 
growth phase.  It was seen that after 3 days, free bacteria had degraded nearly all 
cholesterol, and the encapsulated bacteria degraded 97% of all cholesterol. Tok, et al 
(Tok, 2010) used various strains of Lactobacillus delbrueckii subsp. bulgaricus (ATCC 
11842) for cholesterol degradation for the cases of free and encapsulated bacteria in Ca-
alginate. 
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Table 2. Summary of literature survey to-date of prior cholesterol degradation studies using bacteria. 
 
Study Organism Solvent/Medium Substrate Membrane Degradation Results Reference 
Johnson, 
et al R. equi 
n-propanol, 
BHI Cholesterol Free 80% in 7 days 
Johnson,  
1990 
Johnson, 
et al R. equi 33706 
n-propanol, 
BHI Egg yolk Free 40% in 60 min 
Johnson,  
1990 
Johnson, 
et al R. equi 33706 
n-propanol, 
BHI Milk cream Free 2.36% in 60 min 
Johnson,  
1990 
Bianchi,  
et al 
ATCC 25544, 
4277, DSM20131 
DMF, 
Agar slant Cholesterol 
Free, 
Chitin 
Nearly all in 3 days, 
97% in 3 days 
Bianchi,  
1996 
Tok,  
et al ATCC 11842 
Ethanol, 
MRS Broth Cholesterol 
Free, 
Ca-alginate 
31%, 
31% in 48 h 
Tok,  
2010 
Goetschel, 
et al ATCC 25544 
Aqueous (2,2’-
dipyridal + 
phosphate buffer) 
Cholesterol Free, Liposomes 
33% in 24 h, 
98% in 16 h 
Goetschel, 
1992 
Garofalo,  
et al P. pictorum  Serum Cholesterol 
Free, 
Open pore 
agar, 
Alginate, 
Poly-l-
lysine 
25% in 12 days, 
50% in 12 days 
Garofalo, 
1989 
Gilliland, 
et al L. acidophilus 
Serum, MRS Broth, 
oxgall 
Serum 
Cholesterol N/A 
8-29.8 µg/mL (uptake 
anaerobically), 
No uptake during 
aerobic growth 
Gilliland,  
1985 
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Table 2. (Continued) 
Study Organism Solvent/Medium Substrate Membrane Degradation Results Reference 
Rasic,  
et al 
Str. 
Thermophilus, 
L. acidophilus, 
L. delbrueckii, 
Bif. bifidum 
Serum, 
MRS Broth 
Serum 
Cholesterol N/A 59-276 µg/mL (uptake) 
Rasic,  
1992 
Noh,  
et al L. acidophilus 
MRS Broth + 
Tween80 
Water-soluble 
cholesterol, 
Cholesterol-
phospatidylcho
line micelles 
N/A 7-117 µg/mL (uptake), 8-55 µg/mL (uptake) 
Noh,  
1997 
Tahri,  
et al 
BB536, ATCC 
15697/15700/1
5698/25527/25
525/25910/259
12/25911 
TPY Medium + 
taurocholic acid 
Serum 
Cholesterol N/A 6-50% removal 
Tahri,  
1996 
Tahri,  
et al 
BB536, 
ATCC15700/ 
25527 
TPY Medium + 
oxgall 
Serum 
Cholesterol N/A 
0-3% removal (resting 
cells), 
22-42% (growing cells) 
Tahri,  
1995 
Lin, et al L. acidophilus MRS Medium + bile salts 
Serum 
Cholesterol N/A 
20-57% removal (oxgall), 
43-71% (cholic acid), 
11-52% (taurocholic acid) 
Lin,  
2000 
Strauss N/A (Enzyme mix) Serum Collagen N/A N/A 
Medical 
Breakthroughs, 
2011 
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It was found that a maximum of 31% of total cholesterol was removed. Immobilized 
bacteria were shown to have the greatest rates of cholesterol removal within 48 hours of 
incubation. 
ATCC 25544 was used for cholesterol degradation experiments for aqueous 
dispersion of cholesterol and cholesterol embedded in liposomes (Goetschel, 1992).  33% 
of cholesterol that was dispersed in aqueous medium had undergone conversion after 24 
hours of incubation.  In the case of cholesterol liposomes, 98% was converted after 16 
hours.  Garofalo, et al studied the use of P. pictorum encapsulated in open pore agar 
beads and alginate-poly-l-lysine capsules for cholesterol degradation (Garofalo, 1989).  
As indicated by their results, about 50% of cholesterol was degraded by immobilized 
bacteria as opposed to 25% by free bacteria. 
Gilliland, et al (Gilliland, 1985) studied serum cholesterol removal of various 
strains of L. acidophilus, including GP1B, GP4A, RP43, RP32, C1-5, C2-5, GP2B, P47, 
and S-1.  It was shown that strains C1-5, C2-5, GP2B, and P47 had low cholesterol 
removal with the lowest removal of about 5 µg/mL.  
Rasic, et al (Rasic, 1992) studied the serum cholesterol assimilation of L. 
delbrueckii subsp. bulgaricus (LB1, LB2, LB3), Str. thermophilus (T1, T2), Bif. bifidum 
(BYU, BPO), yoghurt culture (Jog.), and L. acidophilus (AP, AM, AD). LB1 was shown 
to have the highest assimilation of 276 µg/mL over a time period of 20 hours. 
Tahri, et al (Tahri, 1996) showed that strains BB536, ATCC 15697, 15700, 
15698, 25527, 25525, 25910, 25912, and 25911 were able to deplete 40-61% of serum 
cholesterol over a 24-hour time period.  In another study by Tahri, et al (Tahri, 1995), 
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bacterial strains BB536, ATCC 15700 and 25527 were used to study serum cholesterol 
assimilation in the presence of bile salts.  It was shown that ATCC 15700 had the highest 
assimilation of 60%.  It was stated by the authors that the bile salts led to significant 
assimilation. 
Meei-Yn Lin, et al (Lin, 2000) studied serum cholesterol degradation using 
several strains of Lactobacillus acidophilus (ATCC 4356, B, E, Farr, LA-1, and N-1) in 
the presence of different bile salts (oxgall, cholic acid, and taurocholic acid).  The 
combination of strain and bile salt that resulted in the highest degradation ability of about 
71% over a 24-hour duration was that of ATCC 4356 and cholic acid.  
Noh, et al (Noh, 1997) showed that L. acidophilus ATCC 43121 supplemented 
with 92 µg/mL water-soluble cholesterol and oxgall had assimilated 44 µg/mL during 
growth.  When Tween 80 was added, the assimilation was 117 µg/mL.  Cholesterol-
phospatidylcholine micelles (III-E, III-S, Dioleoyl, Distearoyl) were also studied, and it 
was shown that the Dioleoyl type had the highest assimilation of 47 µg/mL.  When 
Tween 80 was added to the micelles, the assimilation was 55 µg/mL. 
The most recent and unique study that is still under development by Strauss 
(Medical Breakthroughs, 2011) is that of a “Liquid Drano,” which consists of an enzyme 
mix that degrades mostly collagen present within atherosclerotic plaque. 
2.6 Cholesterol Degradation Rate 
Kinetics of cholesterol degradation of free and immobilized bacteria will be 
compared.  Cholesterol degradation rates will be expressed in the form of the rate 
equation used to correlate reaction rate with concentration of the reactant species in a 
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chemical reaction (Ebbing, 2010).  In previous research performed by Salva, et al, it was 
found that cholesterol oxidase from Brevibacterium sp. exhibited a first order reaction 
rate (Salva, 1999).  Assume the reaction shown in Eqn. 7.  The cholesterol degradation 
rate, r, is given by Eqn. 8: 
 
 
 
where k is the rate constant of reaction, [A] is the cholesterol concentration and n is the 
reaction order.  
 
 
 
 
 
 
 
 
 
 
 !
!
!! ! ! ! (7) ! ! ! ! ! (8) 
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3.0 RESEARCH OBJECTIVES!
The objectives of this research effort were three-fold: 
3.1 The first objective was to optimize the growth medium for non-immobilized R. 
erythropolis (ATCC 25544) in order to minimize the production of the trehalose 
biosurfactant.   
3.2 The second objective was to devise extraction methods to enable biosurfactant and 
cholesterol quantification for free and immobilized R. erythropolis.  
3.3 The third objective was to assess the effect of capsule miniaturization on cholesterol 
degradation rates supported by statistical significance testing.  
Much research has been conducted on the use of microencapsulation technology 
and bacterium for cholesterol degradation, as documented in the Literature Review 
section.  To date, no cholesterol degradation studies have been performed on 
Rhodococcus erythropolis (ATCC 25544) encapsulated in Ca-alginate beads.  
Additionally, no characterization has been performed on the miniaturization of the 
capsules immobilizing the bacteria.  Most studies in the literature have dealt with 
extraction of cholesterol oxidase produced by bacteria followed by cholesterol 
degradation.  Furthermore, the effects of glycolipid biosurfactant synthesis on the 
encapsulated bacterial growth and activity have not been documented in the literature.  
Since ATCC 25544 has been shown to degrade cholesterol at a high rate (Bianchi, 1996), 
it has been chosen as the strain for this research effort. 
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4.0 MATERIALS AND METHODS!
Described in this chapter are the methodologies undertaken in this research effort.  
Shown in Fig. 6 is the roadmap of this research study from start to finish. 
   
!
 
Figure 6. Roadmap of research study. 
4.1 Materials!
4.1.1 Bacterial Cell Culture!
Rhodococcus erythropolis (ATCC 25544) and LB growth medium were obtained 
from the American Type Culture Collection (ATCC).  Cholesterol powder of 95% purity 
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was obtained from Sigma Aldrich (C7529-25G).  Chemicals used for cell immobilization 
were obtained from Sigma Aldrich. 
An incubator (Heraeus) with CO2 gas was used for all bacterial cultures at 37°C.  
All materials (excluding the bacterium) used in this study were sterilized using an 
autoclave (TOMY SS-320) in order to prevent contamination of live bacterial cell 
cultures.  Prior to experimentation, liquids were further sterilized using a sterile Millipore 
luer-lock, fitted filter attached to a 30-mL syringe. 
Bacterial cell count measurements were carried out on CELL-VU® CBC 
disposable hemacytometers (Millenium Sciences, Inc.) under a Nikon Eclipse Ti-S 
microscope with an attached Andor Technologies camera.  
4.1.2 Preparation of LB Broth Medium!
LB Broth was prepared according to ATCC’s instructions.  The contents of one 
packet were emptied into a clean autoclaved 1000-mL capped glass bottle to which 500 
mL sterile DI water was added.  The bottle was loosely capped and autoclaved. Once 
autoclaved, the bottle was allowed to cool to room temperature with the cap was tightly 
fastened, and stored in a refrigerator at 4°C. 
4.1.3 Preparation of 1X PBS!
1X PBS was prepared by mixing 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g 
KH2PO4 with 800 mL DI water in a sterile clean 1000-mL capped glass bottle.  The pH 
was adjusted to 7.4 by adding enough NaOH as necessary.  The acidity was monitored 
continuously with a pH electrode while adding NaOH.  Once the pH was adjusted to 7.4, 
the total volume of the solution was made to 1000 mL by adding enough DI water as 
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necessary.  The bottle was then autoclaved.  Once autoclaved, the bottle was allowed to 
cool to room temperature with the cap was tightly fastened, and stored in a refrigerator at 
4°C. 
4.1.4 Preparation of 3% (w/v) Sodium Citrate !
A 3% (w/v) sodium citrate was prepared by mixing 3 g sodium citrate dihydrate 
with 100 mL DI water in a sterile clean 200-mL glass beaker.  Once fully mixed, the 
solution was filter sterilized into a sterile Falcon® tube, which was capped tightly and 
stored in the refrigerator at 4°C.  
4.1.5 Quantification Assays!
Assay quantification and optical density measurements were carried out using an 
Agilent 8453 UV-Vis Spectrophotometer.  Plastic cuvettes (FisherBrand, methacrylate, 
1.5-mL, 13-mm path length) were used for all measurements carried out in the visible 
range.  Quartz micro cuvettes (Agilent Ultra Micro 50, Part No. 5062-2496) were used 
for all measurements of samples containing organic solvents. 
The chemicals used for the glycolipid assay were obtained from SJSU and 
consisted of anthrone (Metheson Coleman and Bell), 12.1M hydrochloric acid (HCl), 
concentrated sulfuric acid (H2SO4), chloroform (CHCl3), methanol (CH3OH), and 
acetone.  Cholesterol assays were performed using a cholesterol quantitation kit from 
Abcam (Abcam ab65359).  The contents of the Abcam assay kit consisted of all 
necessary reagents, namely cholesterol standard, cholesterol assay buffer, enzyme mix, 
cholesterol esterase, and cholesterol probe.  
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4.1.6 Software!
The camera software used for size measurements was NIS Elements BR 3.  Data 
analysis for the design of experiment (DOE) and standard formulae were validated using 
Minitab 16.  A MicroFab JetServer was used for inkjet bioprinting of capsules.  Microsoft 
Excel 2011 was used to plot all assay data, calibration curves, and concentration profiles. 
4.2 Bacterial Growth Medium Optimization 
4.2.1 Challenge with Bacterial Growth Measurements!
Bacterial growth measurements were conducted for free and encapsulated bacteria 
in a growth medium composition of LB Broth and BSA as described in Section 4.3.  The 
corresponding growth curves are shown in Fig. 7.  The growth curve of free bacteria is 
shown in blue, and the growth curve of encapsulated bacteria is shown in red. 
 
 
 
Figure 7. Growth curve of free (shown in blue) and encapsulated bacteria (shown in red) 
in regular growth medium (LB and BSA). 
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After 200 h of incubation, measurements of bacterial growth in the encapsulated 
case were impossible to perform due to the presence of a glycolipid biosurfactant that 
breached the capsule membrane as detected visually under the microscope.  Refer to Fig. 
31 in Section 5.4. 
4.2.2 Design of Experiments (DOE) using Taguchi Screening Designs 
 In this research, the technique of Design of Experiments (DOE), specifically 
Taguchi designs, was used to optimize the growth medium composition in order to 
minimize the production of bio-surfactant (response 1) and monitor growth (response 2).  
Taguchi designs are modified orthogonal arrays for robust screening and optimization of 
operating parameters (Roy, 2001).  The type of optimization used was Nominal the Best 
with a target amount of biosurfactant produced of 0 mg.  The formulae needed to conduct 
the optimization based on the Sensitivity (Sm) Signal to noise ratios (S/N), Difference 
(D) and Rank (R) for the Nominal the Best Optimization types are given by Eqns. 9-12 
(Roy, 2001).   
 ! ! ! ! !!!!"!!!! !  (9) 
where D is the difference, i is the element corresponding to the level, j is the element 
corresponding to the factor, S/N (dB) is the signal-to-noise ratio in dB, and L is the total 
number of levels. 
 ! ! !"#$%&% !! !!"#"$%$!!!! (10) 
where R is the rank and nk is the value of response for the k-th response value. 
! "#!
 ! ! !" ! !!" !"#!" !!!!!! !!!!!! ! !!  
(11) 
where S/N (dB) is the signal-to-noise ratio in dB, ! is the mean of response data, nk is the 
value of response for the k-th response value, and N is the total number of replications. 
 !" !" ! !" !"#!" !!! !!  (12) 
where Sm (dB) is the sensitivity in dB, nk is the value of response for the k-th response 
value, and N is the total number of replications.  
The optimal operating level by parameter is determined by ranking the 
importance of each factor based on averaged (Sm) and (S/N) as conducted in the case of 
an ANOVA for traditional orthogonal array analysis.  The ranking scale is an attribute 
scale ranging from one to a maximum possible value equal to the number of factors in the 
experimental matrix.  As the difference (D) increases, the ranking (R) increases.  
 An L16 Taguchi screening design matrix was conducted (Roy, 2001) according to 
the layout in Table 3 with 5 factors [LB Broth (in % vol), BSA (in % vol), PBS (in % 
vol), temperature (in ˚C), and cholesterol concentration (in mg/mL)] and 4 levels for a 
48-hr growth monitoring study period.  The experiments in Table 3 were conducted in 
duplicate.  Optimization types by response are shown in Table 4. 
Following manual calculations and response plot generation for the Sm and S/N 
quantities, the results were validated graphically using Minitab 16.  The expanded 
experimental matrix is shown in Table 5.  The concentration at which cholesterol was 
centered was the high-risk blood cholesterol level of 2 mg/mL (Tahri, 1995).  
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Table 3. L16 Taguchi design (N = 2). 
No Variables Levels 
1 BSA (% vol) 0, 6.6, 13.2, 20.0 
2 LB (% vol) 0, 13.2, 26, 40 
3 1X PBS (% vol) 0, 13.2, 26, 40 
4 CHOL (mg/ml) 0, 13.2, 26, 40 
5 TEMP (°C) 4, 23, 30, 37 !
Table 4. Optimizations type by response. 
Responses Type of Optimization 
Bacterial growth Nominal the best (Target = unknown) 
Amount of bio-surfactant produced Nominal the best (Target = 0) !!!
Table 5. L16 (5 variables, 4 levels) Taguchi matrix for biosurfactant minimization. 
No. BSA  (% vol) 
LB  
(% vol) 
PBS  
(% vol) 
Cholesterol 
(mg/mL) 
Temperature 
(°C) 
Bacteria 
(%vol) 
1 0.0 0.0 0.0 0 4 5.00 
2 0.0 13.2 13.2 3 23 5.00 
3 0.0 26.0 26.0 6 30 5.00 
4 0.0 40.0 40.0 9 37 5.00 
5 6.6 0.0 13.2 6 37 5.00 
6 6.6 13.2 0.0 9 30 5.00 
7 6.6 26.0 40.0 0 23 5.00 
8 6.6 40.0 26.0 3 4 5.00 
9 13.2 0.0 26.0 9 23 5.00 
10 13.2 13.2 40.0 6 4 5.00 
11 13.2 26.0 0.0 3 37 5.00 
12 13.2 40.0 13.2 0 30 5.00 
13 20.0 0.0 40.0 3 30 5.00 
14 20.0 13.2 26.0 0 37 5.00 
15 20.0 26.0 13.2 9 4 5.00 
16 20.0 40.0 0.0 6 23 5.00 
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4.2.3 Experimental Protocol!
An experimental flow diagram of bacteria growth measurements for 
microencapsulated bacteria is shown below in Fig. 8.  In short, equal volumes of 
chloroform:methanol (2:1, v/v) were added to the culture vial, and the vial was shaken 
vigorously.  The contents were filtered through a 100-micron nylon mesh cell strainer in 
order to separate the microcapsules from the culture broth.  The microcapsules were 
rinsed with 3 mL acetone followed by 3 mL DI water.  The acetone and DI water were 
retained.  The microcapsules and culture broth had undergone specific protocols, outlined 
below, in order to obtain growth measurements and glycolipid quantification, 
respectively. 
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Figure 8a. Experimental flow diagram for biosurfactant quantification and bacteria 
growth measurements. 
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Figure 8b. Experimental flow diagram for cholesterol quantification. 
4.2.3.1 Protocol for Growth Measurement !
The microcapsules were removed from the filter and placed into a 20 mL glass 
scintillation vial.  4 mL of 3% (w/v) sodium citrate solution were added to the vial.  The 
vial was then capped and vortexed in order to dissolve the capsules.  The contents in the 
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vial were transferred into 1.5-mL Eppendorf tubes and then centrifuged at 8,000 rpm for 
5 min to separate the bacteria from the liquid.  After centrifugation was complete, the 
supernatant in each tube was removed, thus leaving behind the bacteria pellet.  Each 
pellet was transferred into a fresh clean tube with 1.5 mL of fresh LB Broth and vortexed 
until the pellets were fully dissolved.  After 2X dilution, the bacterial solution was placed 
in a plastic cuvette for spectrophotometric measurement of %transmittance at a 
wavelength of 600 nm using fresh LB Broth as a control.  
4.2.3.2 Glycolipid Extraction and Quantification!
Ristau, et al’s (Ristau, 1983) method of glycolipid extraction was used.  A 
chloroform:methanol (2:1, v/v) was added in equal volume to the bacterial culture, 
shaken vigorously, and allowed to sit in order for the layers to separate.  This resulted in 
a biphasic separation in which case the glycolipid was sandwiched in between the organic 
phase (bottom) and aqueous phase (top) as shown in Fig. 9.  In Fig. 9, the aqueous phase 
was stained with blue dextran for visualization purposes.  
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Figure 9. Biphasic separation of glycolipid biosurfactant.!
The organic phase consisted of chloroform and cholesterol while the aqueous 
phase consisted of the bacteria, culture broth, and methanol (Ristau, 1983).  The organic 
phase was decanted and discarded into a waste container.  1 mL of distilled water was 
added to the remaining glycolipid precipitate and vortexed until dissolved.  0.5 mL of 
each glycolipid precipitate was transferred into separate 40-mL glass scintillation vials 
and subsequently mixed with 0.5 mL DI water.  Each sample was then quantified using 
the Anthrone assay method. 
The culture broth was transferred into 1.5 mL Eppendorf tubes and centrifuged at 
8,000 rpm for 3 min in order to separate the glycolipid from the liquid.  After 
centrifugation, the aqueous and organic phases were removed, thus leaving behind the 
glycolipid precipitate.  All glycolipid precipitates were transferred into a clean tube with 
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1 mL DI water. These samples were then subject to the Anthrone assay for quantification 
of glycolipid as outlined in Section 4.2.1.2.1. 
The Anthrone assay (Ristau, 1983) was used to quantify glycolipids by measuring 
the carbohydrate content present in the sugar moieties.  The assay mechanism (Nigam, 
2007) is shown in Fig. 10.  Hydrochloric acid (HCl) serves to dehydrate the carbohydrate 
into a compound known as furfural, which condenses with Anthrone to form a green 
color, the intensity of which is proportional to the amount of carbohydrate in the sample.  
The intensity of the color is measured through the peak height of the absorbance at a 
wavelength of 620 nm.  The assay was calibrated against glucose standard using the 
following volumetric measurements outlined in Table 6.  
 
Figure 10. Chemical Principle of Anthrone Assay.!
Table 6.  Volumetric measurements for set-up of calibration curve for anthrone assay.!
 
 
 
 
 
 
1.0 mL of each concentration was transferred into separate 40-mL glass 
scintillation vials in triplicate and placed in a laminar flow hood.  2 mL of concentrated 
Vial# 
Concentration 
(mg/mL) 
 
VStock Solution 
(mL) 
VDI Water 
(mL) 
1 0 0.0 1.0 
2 20 0.2 0.8 
3 40 0.4 0.6 
4 60 0.6 0.4 
5 80 0.8 0.2 
6 100 1.0 0.0 
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HCl were added to each vial, which was placed in a boiling water bath for three hours.  4 
mL of 0.2% (w/v) anthrone solution dissolved in cold H2SO4 were added to each vial 
slowly and carefully.  The vials were then placed into a boiling water bath at 100°C for 
15 min.  Once complete, the vials were removed from the water bath and kept in the 
laminar flow hood to cool down and allow the resulting vapor to vent.  Once cooled 
down to room temperature (23°C), a 1.5 mL volume of the contents was transferred into a 
plastic cuvette for optical density spectrophotometric measurements at a wavelength of 
620 nm using DI water as a control.  The peak heights of the absorbance spectra at 620 
nm were plotted against the sample concentrations to yield a calibration curve. 
4.3 Growth Curve of Free and Encapsulated Bacteria 
4.3.1 Free Bacteria 
Growth measurements were setup with the optimized medium.  Samples were 
taken every 24 hours and subsequently diluted 10X prior to absorbance peak height and 
%transmittance measurements using fresh LB Broth as a control.  Next, 0.10 mL of each 
sample were pipetted into a disposable hemacytometer (Fig. 11), allowed to sit for 3 min, 
and taken to a Nikon Eclipse Ti-S microscope for a cell count (Fig. 12).  Cell count 
measurements were taken at five locations, which are circled in red in Fig. 11, and then 
averaged to obtain a cell count.  
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Figure 11.  Cell counting chambers of cbc hemacytometer (drawing not to scale). 
chambers circled at regions where used for cell counting. 
 
 
 
 
Figure 12.  Cell counting chamber of a cbc hemacytometer with live bacteria cells. 
! !
! !!
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 The cell count measurements were then divided by the individual volumes of the 
selected chambers to obtain a cell concentration value in number of cells per mL of 
culture.  The cell concentration was multiplied by the total volume of sample to obtain 
the total cell number, which was plotted against the peak heights of the absorbance to 
construct a calibration curve. 
4.3.2 Encapsulated Bacteria!
Encapsulated bacteria were created using the atomization technique.  As 
described in Section 4.4, 20 autoclaved 40-mL glass scintillation vials were set up in 
triplicate with 5 mL of optimized medium.  Growth measurements were carried out in the 
same manner as in Section 4.2.2.1.  Cell counts were measured, and the growth curve was 
constructed in the same manner as in Section 4.2.4.2.1. 
4.3.3 Bacterial Growth Curve!
 Total bacteria cell number for free and atomized bacteria was plotted against time 
(in days) in order to construct the bacteria growth curve.  
4.3.3.1 Free Bacteria!
A 1 mL of stock bacterial culture was added to 75 mL LB broth and 1 mL BSA in 
a clean autoclaved 125-mL Erlenmeyer flask.  The flask was then loosely capped and 
placed in an incubator at 37°C.  Samples were taken every 24 h starting from the initial 
inoculation.  Each sample was diluted 10x in fresh LB broth and vigorously mixed for 20 
s using a vortex.  Once mixed, the contents were transferred to a disposable plastic 
cuvette.  Peak height absorbance and % transmittance measurements were taken at a 
wavelength of 600 nm using fresh LB Broth as a control.  
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4.3.3.2 Encapsulated Bacteria 
 
The same growth medium from Section 4.2.1 was used for encapsulated bacteria. 
Encapsulated bacteria were placed in autoclaved 40-mL glass scintillation vials in order 
to be set up for destructive sampling. Growth medium was added to each vial in a ratio of 
(75:1, v/v) LB Broth to BSA. 
The capsules were filtered using a 100-µm nylon filter and placed into a 20 mL 
glass scintillation vial.  4 mL of 3% (w/v) sodium citrate solution were added to the vial.  
The vial was then capped and vortexed in order to dissolve the capsules.  The contents in 
the vial were transferred into 1.5-mL Eppendorf tubes and then centrifuged at 8,000 rpm 
for 5 min to separate the bacteria from the liquid.  After centrifugation was complete, the 
supernatant in each tube was removed, thus leaving behind the bacteria pellet.  Each 
pellet was transferred into a fresh clean tube with 1.5 mL of fresh LB Broth.  The tubes 
were vortexed until the pellets were fully dissolved.  After 10X dilution, the bacterial 
solution was placed in a plastic cuvette for spectrophotometric measurement at a 
wavelength of 600 nm using fresh LB Broth as a control. 
4.4  Encapsulation of Bacteria via Atomization and Inkjet Bioprinting 
4.4.1 Atomization!
Bacteria were immobilized by atomization according to the procedure described 
in (Garofalo, 1989).  3% (w/v) alginate was prepared by mixing 3 g of medium viscosity 
alginic acid with 100 mL sterile 0.9% NaCl in a capped 150-mL Erlenmeyer glass flask 
on a stirring plate for 24 h.  Once fully mixed, the flask was autoclaved and allowed to 
cool to room temperature.  Next, 1 mL of bacteria culture was placed into a 1.5-mL 
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Eppendorf centrifuge tube and centrifuged at 8,000 rpm for 5 min.  The supernatant from 
the tube was discarded, and the resulting bacteria pellet was rinsed with DI water by 
vortexing and subsequently centrifuging.  This process was repeated three times. The 
pellet was then transferred into the freshly prepared autoclaved alginate and then mixed 
for 30 min. 
The bacteria-alginate solution was withdrawn into a sterile 10-mL syringe, which 
was then connected to the atomization needle attached to a N2 source.  The syringe-
needle assembly was placed into the syringe pump slot and fixated by actuating the lever.  
The atomization needle tip was oriented toward a 50-mL beaker containing 20 mL 
sterilized 1.5% CaCl2 and situated on a stirring plate (Fig. 13).  An extrusion rate of 0.50 
mL/min was selected on the front panel of the syringe pump.  The N2 source was 
switched on, and the rate of airflow through the atomization needle was set to 12 
mL/min.  
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Figure 13.  Experimental setup for alginate bead fabrication!"
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4.4.2 Inkjet Bioprinting!
Bacteria were immobilized by inkjet printing according to the procedure 
described in (Mobed-Miremadi, 2011).  Shown in Fig. 14 is a picture of the physical set-
up of the inkjet printing scheme.  Microcapsules were fabricated using the Microfab’s 
Jetlab 
 
 
 
Figure 14.  Set-up of inkjet printing scheme.!
System based on the modification of a previously established method, specifically with 
the addition of a physical adsorption step previously established methodology (Mobed-
Miremadi, 2011). The apparatus consisted of a CCD camera (30 fps), a control unit, a 
printhead, a triggering unit, a fluid delivery unit, and a PC equipped with proprietary 
software (MicroFab JetServer) to tune the bio-ink formulation to the jetting parameters. 
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The printhead had an aperture of 60 !m and was rated for !=40 cP and != 72 dyn/cm. 
After inputting the jetting variable settings, droplet generation began with the triggering 
box sending electrical signals to the inkjet control unit and to the CCD camera control 
PC, simultaneously. The inkjet engine fired the 0.5% (w/v) filter-sterilized low viscosity 
sodium alginate solution [!=5 cP, != 43 dyn/cm] mixed with bacteria (1 ml centrifuged 
bacteria/ml of alginate), into a 15% (w/v) CaCl2 receiving solution. The beads were 
allowed to cross-link for 30 min.  Following the cross-linking step, 1% (w/v) low 
viscosity chitosan was added into the receiving  solution to make the final chitosan 
concentration 0.5% (w/v). This physical adsorption step was carried out for 30 min at 
room temperature using stirring was necessary to confer mechanical strength to the 
suspension during the subsequent concentration and centrifugation steps. The capsules 
were then centrifuged at 8,000 rpm for 5 min and washed with a 0.9% (w/v) NaCl 
solution 3 times.  
The source of N2 gas was turned on, and the airflow was set to 20 psi.  The 
printhead underwent rinses with isopropyl alcohol, DI water, and 0.9% NaCl, each 
performed three times and in series in that order.  The printhead was rinsed by first filling 
the syringe with the appropriate liquid and then setting the 1st knob on the inkjet printer to 
“ON” and “PURGE.”  Any clogs that were present in the printhead were mitigated by 
connecting the tubing output from the syringe directly onto the print head and manually 
purging it with 0.9% NaCl.  Once rinsing and any clogs were completed, 5-mL bacteria-
alginate mixture was put into the syringe.  Input parameters shown in Fig. 15 were 
entered in the MicroFab JetServer™ software. 
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Figure 15.  Input parameters for inkjet bioprinting system using microfab jetserver ™.!
The “PURGE” setting was enabled and the 1st knob was set to “ON.”  The 
vacuum pump was then switched on and set to 25 psi.  The backpressure was adjusted as 
necessary until the meniscus on the print head tip appeared to be flat.  The external lamp 
was dimmed, and the strobe light was set to 200 µs.  “START JETTING” on the software 
was then selected, and the voltage was adjusted as necessary until capsules were visible 
as shown in Fig. 16.  Capsules were jetted for 2 h into a petri dish filled with 7 mL 
sterilized 15% CaCl2.  After 2 h of jetting, the capsules were allowed to sit in the 15% 
CaCl2 solution for 30 min in order to undergo cross-linking.  After cross-linking, the 
capsules were placed into a sterile Falcon® tube containing 10 mL of 1% (w/v) chitosan 
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solution and allowed to sit for 30 min in order to be coated.  After coating was complete, 
the contents of the tube were transferred into 1.5-mL Eppendorf centrifuge tubes, capped, 
and centrifuged at 8,000 rpm for 3 min.  Once centrifugation was complete, the 
supernatant solution from each tube was discarded, and the capsules were consolidated 
into a single 1.5-mL Eppendorf centrifuge tube to which 1-mL 0.9% NaCl was added.  
 
 
Figure 16. Close-up view of inkjet printhead ejecting encapsulated bacteria. 
4.4.3 Encapsulation Efficiency!
An encapsulation efficiency experiment was conducted in order to understand 
how many of the initial cells mixed in the alginate were retained in the capsules after 
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crosslinking.  In order to do so, 1 mL of a known concentration of bacteria infused in 
alginate was atomized into microcapsules using the procedure from Section 4.2.2.  The 
capsules were then placed in an autoclaved 20-mL glass scintillation vial.  4 mL of 3% 
(w/v) sodium citrate was added to dissolve the capsules.  The vial was then capped tightly 
and vortexed until the capsules were fully dissolved.  The contents of the vial were then 
added into 1.5-mL Eppendorf centrifuge tubes, which were then centrifuged at 8,000 rpm 
for 5 min.  The supernatant was then discarded, and the resulting bacteria pellets were 
collected into a single fresh falcon tube in which they were re-suspended in fresh LB 
Broth, then vortexed until fully dissolved.  The absorbance of the bacteria was measured 
by way of spectrophotometry at a wavelength of 600 nm using fresh LB Broth as a 
control.  The peak absorbance value was recorded and, the total cell number was 
calculated by way of the calibration curve in Section 5.1.1.  Eqn. 13 was used to 
determine encapsulation efficiency: 
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4.5 Cholesterol Degradation Experiments 
Cholesterol degradation experiments were conducted in three different scenarios:  
1. Free bacteria in optimized medium, 
2. Encapsulated bacteria via atomization, and 
3. Encapsulated bacteria via inkjet bioprinting.  
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The purpose of these experiments was to study the effects of miniaturization on 
cholesterol degradation.  The effects of cell number on cholesterol degradation were also 
studied. 
4.5.1 Experimental Set-up!
The cell counts from the lag, log, and peak growth were chosen from the bacteria 
growth curve in Section 5.1.  To obtain the cell counts at those regions, 1.5 mL aliquots 
of fresh bacteria culture were first diluted in fresh LB Broth.  Peak absorbance values 
were measured at 600 nm using fresh LB Broth as a control.  The cell count was 
calculated and verified using the calibration curve.  The cells were then placed in 1.5 mL 
Eppendorf tubes and centrifuged at 8,000 rpm for 4 min.  Once complete, the supernatant 
liquids were discarded, and 1.5 mL sterile DI water were added to each tube, which was 
then capped and vortexed for 20 sec to re-suspend the cells.  The tubes were then 
centrifuged again at 8,000 rpm.  The process of washing the cells with DI water was 
repeated for a total of three washes in order to ensure no remnants from the previous 
growth medium were present.  
For the case of cholesterol degradation by free bacteria, the cells were suspended 
in 2 mL fresh LB by vortexing for 1 min.  The cells were then transferred to autoclaved 
40-mL scintillation glass vials and set up in triplicate as outlined in Table 7.  
Table 7.  Set-up parameters of cholesterol degradation experiment (N = 3). 
 
Phase on Growth Curve from which 
Cell Count was Selected Incubation Time (days) 
Lag (Nlow = 4.53 x 108) 2 5 8 
Log (Nmed = 6.90 x 108) 2 5 8 
Stationary (Nhigh = 1.76 x 109) 2 5 8 
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The specified cell counts in Table 7 were harvested and mixed into multiple fresh 
autoclaved alginate mixtures, one per vial, which were then subjected to encapsulation. 
Bacteria were encapsulated via atomization in the same manner as described in Section 
4.2.2.  For inkjet bacteria, the low cell count was used.  All samples for atomized and 
inkjet bacteria were set up in triplicate. 
4.5.2 Cholesterol Layer Identification!
The phase in which cholesterol was to be extracted was determined through 
Salkowski’s reaction (Romley, 1903).  The principle of Salkowski’s reaction is that the 
double bond in cholesterol reacts with concentrated sulfuric acid to give bicholestadien 
disulphonate, which is pink to dark magenta in color.  Shown in Fig. 18 is a series of 
glass test tubes filled with different mixtures of solutions and the phase in which 
cholesterol was present. As described in Salkowski’s reaction, reaction of cholesterol 
with H2SO4 caused the cholesterol to appear pink to dark magenta in color.  When H2SO4 
was added to cholesterol dissolved in chloroform, the chloroform layer appeared 
magenta, indicating that cholesterol was present in that layer.  When chloroform and 
H2SO4 were added to whole culture broth, encapsulated bacteria, and cholesterol, the 
chloroform layer once again appeared magenta in color, thereby confirming that the 
cholesterol was consistently present within that layer.  Hence, cholesterol extraction was 
performed from the chloroform phase.  
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Figure 17.  Cholesterol phase identification using salkowski’s method (1-cholesterol 
powder, 2-sulfuric acid, 3-chloroform, 4-culture broth, 5-capsules, 6-methanol, 7-water).!
 
4.5.3 Cholesterol Quantification!
Quantification of cholesterol was carried out by way of a colorimetric assay kit 
from Abcam.  The Abcam assay kit utilizes the mechanism of cholesterol quantification 
as follows.  In summary, cholesterol reacts with cholesterol oxidase enzyme in the 
presence of O2 to produce 4-cholesten-3-one and H2O2.  H2O2 reacts with the provided 
cholesterol probe to produce resorufin, which is pink in color.  The intensity of the pink 
color is proportional to the amount of cholesterol present in solution.  The intensity was 
measured through the peak values of the absorbance at a wavelength of 570 nm.  
All contents of the assay were warmed to room temperature in a shaker until 
thawed.  The vials containing cholesterol esterase and enzyme mix were each dissolved 
in 220 µL of cholesterol assay buffer.  A 0.25 µg/µL stock solution of cholesterol 
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standard was prepared by mixing 20 µL of cholesterol standard with 140 µL cholesterol 
assay buffer and vortexing for 1 min. A calibration curve was constructed by adding the 
volumes of cholesterol standard and cholesterol assay buffer outlined in Table 8 into a 
series of 1.5 mL Eppendorf centrifuge tubes, which were labeled accordingly. 
Table 8.  Volumetric measurements of set-up for calibration curve of abcam cholesterol 
assay. !
Tube # Mass of  Cholesterol (µg) 
VCholesterol Standard 
(µL) 
VCholesterol Assay Buffer 
(µL) 
1 0 0 50 
2 1 4 46 
3 2 8 42 
4 3 12 38 
5 4 16 34 
6 5 20 30 
 
The reaction mix was prepared by adding 44 µL cholesterol assay buffer, 2 µL 
cholesterol probe, 2 µL enzyme mix, and 2 µL cholesterol esterase into a 1.5 mL 
Eppendorf centrifuge tube and vortexing for 1 min.  Enough reaction mix was prepared 
such that there were 50 µL per sample being assayed. 50 µL of reaction mix was added to 
each tube and vortexed for 10 sec.  After mixing, the tubes were placed in the incubator 
at 37°C for 60 min.  Once incubation was complete, the tubes were removed from the 
incubator and vortexed.  Optical density spectrophotometric measurements were 
conducted in the quartz glass cuvette at 620 nm using 100 µL cholesterol assay buffer as 
a control sample.  The peak absorbance values were recorded.  Samples were diluted with 
cholesterol assay buffer as necessary in order to keep the absorbance at a maximum value 
of 1.0. 
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5.0 RESULTS  
5.1 Growth medium Optimization and Validation  
5.1.1 Optimization  
Shown in Fig. 18 is the Sm plot for glycolipid biosurfactant production after 48 h 
of incubation for BSA, LB, PBS, Cholesterol, and Temperature.  The amounts of 
biosurfactant are represented by the y-axes.  The corresponding S/N plots for 
biosurfactant production are shown in Fig. 19.  Similarly, the Sm and S/N plots for 
bacterial growth, with y-axes for all Sensitivity plots representing the %T are presented in 
Figs. 20 and 21, respectively.  The analyses for biosurfactant production and bacterial 
growth are presented in Tables 9 and 10.  The raw data for both responses are tabulated in 
Appendix B. 
 
Figure 18.  Sensitivity plot for BSA, LB, PBS, cholesterol, and temperature on 
biosurfactant production. 
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Figure 19.  Signal-to-noise ratio plot for BSA, LB, PBS, cholesterol, and temperature on 
biosurfactant production. 
 
 
Figure 20.  Sensitivity plot for BSA, LB, PBS, cholesterol, and temperature on bacteria 
growth. 
20 
22 
24 
26 
28 
30 
32 
34 
36 
1 2 3 4 
S/
N
 (d
B
) 
Level 
Temperature 
BSA 
LB 
PBS 
Cholesterol 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
1 2 3 4 
Sm
 (d
B
) 
Level 
BSA 
LB 
PBS 
Cholesterol 
Temperature 
! "#!
!
 
Figure 21.  Signal-to-noise ratio plot for BSA, LB, PBS, cholesterol, and temperature on 
bacteria growth
 
 
! ""!
 
Table 9.  Summary of Taguchi analysis of biosurfactant production using the nominal the best optimization type. 
 
Variable Delta Rank 
Optimal 
Level 
Based 
on Sm 
Delta Rank 
Optimal 
Level 
Based 
on S/N 
Theoretical 
Optimal 
Level of 
Operation 
Selected 
Level of 
Operation 
BSA 210 5 2 3.54 5 4 2 2 
LB 305 4 4 10.0 1 2 2 2 
PBS 600 1 2 8.11 3 2 2 2 
CHOL 597 2 1 9.14 2 1 1 2 
TEMP 575 3 1 7.31 4 2 1 4 
 
 
Table 10.  Summary of Taguchi analysis of bacterial growth using the nominal the best optimization type. 
Variable Delta Rank 
Optimal 
Level 
Based 
on Sm 
Delta Rank 
Optimal 
Level 
Based 
on S/N 
Theoretical 
Optimal 
Level of 
Operation 
Selected 
Level of 
Operation 
BSA 1.70 3 3 8.63 4 3 3 2 
LB 0.84 4 2 8.69 3 4 4 2 
PBS 0.22 5 2 6.83 5 1 1 2 
CHOL 2.06 2 1 18.4 1 3 3 2 
TEMP 7.99 1 1 15.8 2 1 1 4 
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5.1.2 Validation using Minitab 
Shown in Figs. 22 and 23 are the main effects plot for means and signal-to-noise 
ratios for biosurfactant at 48 h, respectively.  As can be seen, the trends are identical to 
the data presented in Figs. 18 and 19.  Hence, the optimization method using Excel was 
validated.  
 
Figure 22.  Main effects plot for means of glycolipid biosurfactant for t = 48 h. 
 
! "#!
 
 
Figure 23.  Main effects plot for signal-to-noise ratios of glycolipid biosurfactant for t = 
48 h.!
5.2 Bacteria Growth Study 
5.2.1 Calibration Curve!
The triplicated calibration curve of bacteria cell number (N) determined by the 
CBC hemacytometer is related to the optical density (OD) at 600 nm (Fig. 24) and is 
given by Eqn. 14: 
 !"##! "#$%& ! !!!!"!!"!!""!!"! ! !!!"!. (14) 
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Figure 24.  Calibration curve of bacterial cell count in optimized medium.!
5.2.2 Encapsulation Efficiency 
 
It was determined that 86.2% of the cells that mixed into the alginate mixture 
prior to atomization were immobilized within the capsules.  The encapsulation efficiency 
for the inkjet bacteria is not available since the methodology has not been developed to 
date.  
5.2.3 Growth Curve!
5.2.3.1 Growth Curves Prior to Growth Medium Optimization!
Shown in Fig. 25 is the growth curve of free bacteria (blue) and encapsulated 
bacteria (red) in regular growth medium, which consisted of LB Broth and BSA.  Death 
phase begins at 45 h with the bulk of the encapsulated population decimated at 212 h as 
compared to the onset of the decay phase occurring at 288 h for the free bacteria.   
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Figure 25.  Growth curve of free (shown in blue) and encapsulated bacteria (shown in 
red) in regular growth medium (LB and BSA).!
It is important to note that bacteria growth was initially conducted in a shaker at 
37ºC with the prospect that biosurfactant would emulsify.  It was observed, however, that 
the bio-surfactant did not emulsify but in fact coalesced with the alginate membrane.  In 
order to obtain a viable solution for immobilized bacterial growth, the DOE elaborated 
upon in the previous section was devised.  
5.2.3.2 Growth Curves Post Growth Medium Optimization 
Shown in Fig. 26 is the growth curve for free bacteria (red) and encapsulated 
bacteria (blue) in optimized growth medium.  The regions circled in purple at t = 2, 5, and 
8 correspond to the lag phase, log phase, and stationary phase, respectively.  As can be 
seen, the lag and log phases seem to follow the typical growth behavior.  However, the 
stationary phase seems to be short-lived.  It is important to note that such atypical growth 
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behavior is possible since the growth medium was altered in order to minimize the 
amount of biosurfactant by-product that is naturally created by the bacteria (Shuler, 
2002).   
From the calibration curve, total cell numbers were obtained and were plotted 
against time for both free and microencapsulated bacteria, thus constituting the bacteria 
growth curve shown in Fig. 26.  As can be seen for the free bacteria, there was a lag 
phase of 3 days, a log phase from 5-7 days, and a peak growth observed at 8 days, which 
was the short-lived stationary phase.  It can be seen that growth of microencapsulated 
bacteria was characterized by a lag compared to that of free bacteria.  Such a 
characteristic is indicative of the diffusion barrier provided by the alginate membrane.  
From the curve, it was inferred that the bacteria were able to survive in the encapsulated 
state as a result of growth medium optimization. 
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Figure 26.  Growth curve of free (shown in red) and encapsulated bacteria (shown in blue) in optimized medium.
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5.3.1 Calibration Curve 
Shown in Fig. 27 are the colorimetric products of the anthrone assay when 
calibrated against the glucose standard at concentrations of 0-100 mg/mL (left to right).  
As the concentration of glucose increases, the color of the reaction gains a darker green 
tone.  As shown in Fig. 28, the triplicated spectrophotometric calibration curve 
correlating absorbance (A) to the glucose standard concentration is linear and given by a 
correlation given by Eqn. 15. 
 !!"# ! !!!!"#! !"#$%#&'(&)"#!!"!!"#$%&'!!"#$%#&%!!!" !"!                  (15) 
 
        
Figure 27.  Calibration curve samples of anthrone assay for a glucose concentration range 
of 0-100 mg/mL (left to right). 
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Figure 28.  Calibration curve of anthrone carbohydrate assay against glucose standard. 
5.3.2 Glycolipid Profile For Encapsulated Bacteria 
Shown in Fig. 29 is the mass profile of glycolipid produced by atomized bacteria 
over time.  As can be seen, the glycolipid production stabilized after 7 days, thus 
confirming the validity of the DOE optimization parameters.  The experiment was 
performed in duplicate (N = 2) starting from an initial cell count of N = 2.06 x 10 7, and 
destructive sampling was employed.  An S-Shaped trend is detected with the glycolipid 
mass being asymptotic at 50 mg between days 6 and 10 days.  It could be observed that 
80% of the glycolipid production occurs the first 2 days.   
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Figure 29.  Mass profile of glycolipid for atomized bacteria.!
5.4 Cholesterol Degradation Studies!
As shown in Fig. 30, microcapsules fabricated by atomization had an average 
diameter of 850 ±50 µm and had a thickness of 6 µm.  A total of 30 microcapsules were 
examined to calculate the dimensional statistics.  Shown in Fig. 31 are the encapsulated 
bacteria in culture broth at 4X magnification.  As can be seen, the glycolipid 
biosurfactant and cholesterol powder adsorbed onto the surface of the alginate capsules. 
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Figure 30.  Atomized bacteria (at 10X) used throughout the study (before experiment). 
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Figure 31.  Atomized bacteria (at 4X) in culture broth after t = 8 days of incubation 
(before extraction). 
 
Shown in Fig. 32 are the same capsules at 10X magnification from Fig. 31 after 
treatment with (2:1, v/v) chloroform:methanol.  As can be seen, the medium is free of 
glycolipid biosurfactant and cholesterol, and the alginate membranes appear to be intact. 
Shown in Fig. 33 are the capsules at 20X magnification fabricated by inkjet printing.  The 
capsule diameter was 32 ± 5 !m based on 30 examined capsules. In comparison to the 
atomized capsules (Fig. 30), a lower bacterial cell density can be observed in the inkjet 
capsules as presented in Fig. 35.  Since the surface area-to-volume ratio increases with 
miniaturization, a smaller core volume is available for growth. 
!"#!
 
 
Figure 32.  Atomized bacteria (at 10X) after 8 days of incubation (after extraction). 
 
 
Figure 33.  a) Encapsulated bacteria (at 20X) fabricated by way of inkjet printing, 
b) magnified bacterial cells (at 60X) within miniaturized capsule (individual cells labeled 
with arrows.) 
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5.4.1 Cholesterol Quantification 
 
Shown in Fig. 34 is the triplicated calibration curve for the Abcam Cholesterol 
Quantitation Kit.  The correlation of absorbance (A) regressed against the mass of 
cholesterol (µg) is linear and is characterized by the following equation (Eqn. 16): !!"#!!" ! !!!!"!! !"##!!"!!!!"#$%#&!"! !" !! (16) 
 
 
Figure 34.  Calibration curve for abcam cholesterol quantitation kit. 
5.4.2 Cholesterol Degradation Profiles!
5.4.2.1 Degradation Rate Calculations!
Shown in Fig. 35 is a sample cholesterol degradation rate plot for atomized 
bacteria for an initial cell count of N = 4.53 x 108.  As mentioned in the Methods section 
destructive sampling was conducted at days 2, 5 and 8 corresponding to the lag, log and 
stationary phases of the growth curve presented in Fig 26.  Since the bulk of glycolipid 
growth occurs within the first 2 days according to Fig. 29, for analytical purposes it will 
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be assumed that the 0-2 day interval corresponds to the period of free cholesterol 
diffusion (period 1) through the capsule membrane and the 2-8 day period (period 2) 
corresponds to the glycolipid-mediated transport period.  Although degradation rates for 
both periods were analyzed, emphasis was placed on the free diffusion period.  
Furthermore since the Stokes’ radius of cholesterol (a = 0.54 nm) is an order of 
magnitude smaller than the microcapsules pores (a = 5 nm for atomized and a = 8 nm        
for inkjet) (Simpliciano, 2012), diffusion resistance will not be taken into account in rate 
calculations.  The rate equations, kinetic constants (when applicable) and regression 
coefficients for free and immobilized bacteria are presented in Tables 11 and 12.  
Table 11.  Degradation rates of cholesterol by free, atomized, and inkjet bacteria for  the 
free diffusion phase at Nlow (4.53 x 108). 
 
Bacteria 
Immobilization State Free Atomized Inkjet 
Rate Equation dC/dt = -0.1502 [C]0 
dC/dt = 
-0.1109 [C]0 
dC/dt = 
-0.6025 [C]0 
Zero Order Kinetic 
Constant (mg mL-1 
day-1) 
0.1502 0.1109 0.6025 
 
Table 12.  Degradation rates of free, atomized, and inkjet bacteria for the glycolipid-
mediated transport phase at Nlow. (4.53 x 108). 
 
Bacteria 
Immobilization 
State 
Free Atomized Inkjet 
Rate Equation dC/dt = -0.0313 [C]0 
dC/dt = 
-0.0901 [C]0 
dC/dt = 
-0.0259 [C]0 
Regression 
Coefficient 0.933 0.999 0.866 
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Since the profiles for both period were linear by design or regression analysis, the 
reaction order, n, is equal to zero, thereby rendering them as zero-order equation. 
5.4.2.2 Effect of Initial Cell Count on Cholesterol Degradation 
 
Prior to the encapsulation experiments statistical significance testing using a 
student t-test (Dalgaard, 2008) was conducted on free bacteria to determine the effect of 
initial cell count on cholesterol degradation.  In this case, the null hypothesis (H0) was 
that there is no significant difference between initial free bacteria cell count and amount 
of cholesterol degraded.  The alternate hypothesis (H1) was that there would be a 
difference in cholesterol concentration as cell number was varied.  For all t-test studies, 
95% confidence was assumed, thus rendering ! = 0.05.  The same followed for the 
atomized bacteria (Table 13).  Metabolite degradation plots at Nlow (4.53 x 108), N med 
(6.90 x 108), and Nhigh (1.76  x109) are presented in Fig. 36.  The reduction in the mass of 
cholesterol during the 0-2 day period (period 1) was used to conduct the significance 
testing.  As shown in the graphical trends, more specifically the super-imposition of the 
plots and results of the significance testing shown in Table 13, the null hypothesis (H0) 
failed to be rejected for all 3 pairwise comparisons because of p-values being greater than 
!.  
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Figure 35.  Normalized cholesterol concentration profile as a function of time for free 
bacteria (NLow). 
 
Table 13.  Significance testing summary comparing the effect of cell count to cholesterol 
degradation for the free bacteria. 
Scenario Nlow vs. Nmed 
Nlow vs. 
Nhigh 
Nmed vs. 
Nhigh 
! 0.05 0.05 0.05 
T-value -0.55 0.24 1.65 
p-value 0.635 0.83 0.242 
 
5.4.2.3 Cholesterol Degradation for Immobilized Bacteria !
As proven above, since the effect of initial cell count was negligible on 
cholesterol degradation rate, it was decided to conduct bacterial immobilization at lower 
cell count to prevent nozzle blockage during the jetting portion of the microencapsulation 
processes.  Metabolite degradation plots at Nlow (4.53 x 108) are presented for the 
atomized and inkjet-printed bacteria Fig. 36.  The profiles can be described by the same 
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two regions used to describe free bacteria behavior.  The first is delimited by the 0-2 day 
and the second by the 2-8 day time periods.  The reduction in the mass of cholesterol 
during period 1 was used to conduct the significance testing between the two types of 
immobilization methods.  The null hypothesis, H0 was that there would be no significant 
difference in cholesterol removal at day 2 between the atomized and inkjet-immobilized 
bacteria.  The alternate hypothesis, H1, was that there would be a difference in cholesterol 
removal at day 2 between the atomized and inkjet-immobilized bacteria.  As seen in 
Table 14, the reduction in capsule diameter has a significant effect on cholesterol 
degradation rate. 
 
 
 
Figure 36.  Cholesterol degradation profiles for free and immobilized bacteria as a 
function of time for Nlow = 4.53 x 108. !!
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Table 14.  Summary of t-test significance testing for the effect of capsule miniaturization 
on cholesterol degradation rates at Nlow = 4.53 x 108. 
Scenario Atomized vs. Inkjet 
T-value 5.9 
p-value 0.028 
Accepted Hypothesis H1 
 
5.4.2.4 Synopsis of Cholesterol Degradation Results   
A synopsis of cholesterol degradation results in terms of percent decrease as a 
function of bacterial immobilization state is presented in Table 15.  A monotonous 
decrease in metabolite was observed for all initial cells counts and immobilization states. 
Focusing on the low cell count (Nlow) category, throughout sampling intervals, the 
percent decrease was greatest for the inkjet-printed bacteria. 
Table 15.  Percentage degradation of cholesterol mass for free, atomized, and inkjet 
bacteria in optimized medium. 
 
 Free Bacteria Atomized Inkjet 
Time 
(days) NLow NMed NHigh NLow NLow 
0 - - - - - 
2 22.8%±0.62% 19.9%±0.07% 23.6%±0.46% 16.8%±0.19% 57.7%±0.21% 
5 26.6%±0.25% 39.6%±0.65% 31.1%±0.69% 37.8%±0.83% 63.9%±0.15% 
8 37.0%±0.42% 52.0%±0.66% 54.6%±0.41% 57.8%±0.04% 65.1%±0.01% 
 
5.4.2.5 Prediction of Cholesterol Removal in Plaque Based on the Current Models 
Shown in Table 16 is the estimated percentage of cholesterol removed from 
plaque within 8 days, assuming that the lesion is composed of 22% cholesterol (Kaiz, 
1976) and that the combined degradation rate equations in Tables 11 and 12 are used in 
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Table 16 for the atomized and inkjet bacteria were calculated per mL of alginate.  As can 
be seen, the inkjet case resulted in the highest degradation of cholesterol in plaque within 
the 8-day duration.  
Table 16.  Estimated time to fully degrade cholesterol from intermediate-stage plaque 
lesion.!
  
Free Bacteria Atomized Inkjet 
NLow NMed NHigh NLow NMed NHigh NLow 
%Cholesterol 
Removed 22.19% 34.65% 31.23% 41.51% 32.70% 38.53% 61.80% 
 
5.5 Partition Coefficient Determination 
Shown in Table 17 and Fig. 37, are the partition coefficients of cholesterol 
extracted from water into chloroform according to the scheme in Fig. 5 at various 
sampling times.  Theoretically, the partition coefficient is a constant and should not vary 
unless a new component is introduced in the mixture or there is a change in pH or 
temperature, thus shifting the solubilities (Harrison, 2003).  A decrease in K values is 
observed for the free and immobilized bacteria as a function of time.  Two hypotheses 
could be formulated to justify this observation: 1) The biosurfactant is amphipathic and 
thus the cholesterol has adsorbed upon to the bio-surfactant itself and was not stripped off 
by the chloroform during extraction, and/or, 2) The hydrophobic cholesterol adsorbed to 
the alginate membrane was not stripped off during the same extraction process.  Both 
hypotheses lead to the presence of residual amounts of solute due non-ideal efficiency of 
extraction procedures.  Since the same monotonous trend is observed in all scenarios, it is 
safe to attribute the root cause of the K value decrease to a systematic error.  The average 
!"#!
partition coefficient for the inkjet-immobilized bacteria is lower during the entire 
sampling interval.  This could be due to the presence of chitosan in the immobilized 
matrix, absent in case of the atomized alginate.  The extraction protocol needs to be 
further optimized to take the presence of this additional bio-polymer coating into account. 
Table 17.  Average partition coefficients of cholesterol extracted from water into 
chloroform (N = 3). 
Partition Coefficient (K) 
Time  
(days) 
NLow  
Free 
NLow  
Atomized 
NMed  
Free 
NHigh  
Free Inkjet 
0 1.64E+01 1.64E+01 1.64E+01 1.64E+01 5.12E+00 
2 4.74E+00 6.10E+00 5.34E+00 4.58E+00 3.20E+00 
5 4.08E+00 2.70E+00 2.53E+00 3.43E+00 2.25E+00 
8 2.78E+00 1.32E+00 1.63E+00 1.49E+00 2.11E+00 
 
      
Figure 37.  Experimentally determined partition coefficient of cholesterol extracted from 
water into chloroform. !
0.00 
2.00 
4.00 
6.00 
8.00 
10.00 
12.00 
14.00 
16.00 
18.00 
0 2 4 6 8 10 
E
xp
er
im
en
ta
lly
 D
et
er
m
in
ed
 
Pa
rt
iti
on
 C
oe
ffi
ci
en
t (
K
) 
Time (days) 
Medium Free 
Low Free 
High Free 
Atomized Low 
Inkjet Low 
!"#!
6.0 DISCUSSION!
The studies from the literature that compared most closely with this study were 
those of Goetschel, et al and Bianchi, et al.  Goetschel, et al, reported a 33% degradation 
of cholesterol in 24 h in aqueous medium by free bacteria.  Bianchi, et al reported that 
free and chitin-encapsulated R. erythropolis converted nearly all and 97% of total 
cholesterol, respectively, within 3 days.  
The percentage degradation data reported in Table 15 for the first 48 h were 
slightly lower but not significantly different from the 33% reported by Goetschel, et al. 
The percentage degradation reported by Bianchi, et al, however, was much greater than 
that of the data reported in this study.  Several factors may have contributed to these 
differences. The first thing to note is that Bianchi, et al did not specify the initial amount 
of cholesterol that they used.  Assuming the rate of cholesterol degradation did not 
change with the amount of cholesterol present within the system, if a small initial amount 
of cholesterol was used, less time would be required for it to be degraded.  Second, 
Bianchi, et al used a BHI growth medium, whereas LB Broth, PBS, and BSA were used 
in this study.  Hence, growth characteristics were expected to be different.  Changes in 
growth characteristics would include differences in the enzyme production and cell 
survivability.  Perhaps, the most important thing to consider is that the optimized medium 
in this study was designed to decrease the amount of biosurfactant being produced.  Since 
the biosurfactant is amphipathic, it is possible that it played a role in cholesterol 
degradation.  With regards to the case of encapsulated bacteria, Bianchi, et al worked 
!""!
with chitin polymer as opposed to Ca-alginate, which was used in this study.  Hence, 
there is no baseline from which a conclusion may be reached.  
Prior to the bio-surfactant minimization efforts, it was initially hypothesized that 
cholesterol diffusion could be described using Fick’s Second Law of Diffusion.  
However, due to bio-surfactant growth the extent of diffusive and kinetic mechanisms 
contributing to cholesterol degradation was considered as a lump degradation 
mechanism.  It is possible that the biosurfactant may have aided in some type of co-
transport mechanism whereby hydrophobic cholesterol was physically transported from 
the medium into the capsule where it could have been degraded by bacteria.  More 
studies would need to be conducted in order to understand the interaction of biosurfactant 
with cholesterol degradation.  Due to the enhanced metabolic capability of the 
miniaturized inkjet capsules immobilizing the bacteria, the above-stated hypothesis is 
partially validated.  This observation is in alignment with the results of a recent study on 
fluorescent MW markers demonstration a 4-fold diffusivity increase across miniaturized 
alginate beads (Mobed-Miremadi, 2012). 
The following hypotheses justifying the higher degradation rates for the bacteria 
immobilized using the inkjet process could be formulated:  
i. The S/V ratio of inkjet bacteria was 26 times higher than that of the atomized bacteria; 
ii. Hydrophobic cholesterol adsorbs onto the surface of the capsules; 
iii. The pore size range for both capsules has been measured to be approximately 6 nm.  
The Stoke’s radius of cholesterol is a = 0.54 nm, hence the metabolite can freely diffuse. 
!"#!
iv. The presence of the chitosan membrane may have also had some interaction with the 
cholesterol, which would require further investigation.  
Cholesterol degradation using the low bacterial cell count condition during the lag 
phase may have mostly occurred by way of the intracellular enzyme from t = 0 to t = 5 
days.  It is likely that by the time the last measurement was taken at t = 8 days, the 
bacteria were beginning to produce the extracellular enzyme.  Encapsulating bacteria 
harvested from the plateau phase by way of inkjet bioprinting followed by a cholesterol 
degradation study would confirm this hypothesis.  Furthermore, the molecular weight of 
the cholesterol oxidase enzyme is below the molecular weight cut-off of alginate, which 
is approximately 70 kDa, so it is possible that the extracellular enzyme had diffused out 
of the capsules and degraded cholesterol in the medium.  More studies would need to be 
conducted in order to confirm this postulated hypothesis.  
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7.0 POSSIBLE CONTRIBUTIONS TO KNOWLEDGE!
• The composition of bacteria growth medium was optimized in order to minimize the 
production of biosurfactant.  Without this optimization, the cholesterol degradation 
studies would have been hindered. 
• To date, the only membranes used to encapsulate R. erythropolis (ATCC 25544) were 
chitin and liposomes as compared to Ca-alginate, which was used in this study.  
Studies of cholesterol degradation with encapsulated bacteria have not been 
characterized for the case of miniaturization, which has been proven to be the most 
effective alternative for medical applications.  
• One of the major feats of this research was overcoming the hydrophobic nature of the 
cholesterol powder suspended in the aqueous medium.  It was the hydrophobicity of 
the cholesterol that necessitated the use of destructive sampling throughout 
experimentation.  Custom extraction layer identification and protocols have been 
developed. 
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8.0 CONCLUSIONS AND FUTURE WORK 
8.1 Conclusion  
Initially, bacterial cell growth was hindered due to biosurfactant production as a 
metabolic by-product.  The constituents of the growth medium were optimized using an 
L16 Taguchi design in order to minimize the production of biosurfactant with the 
intention of characterizing growth data for free and atomized bacteria.  The validity of the 
biosurfactant minimization efforts was proven by the stabilization of the amount of 
trehalose-glycolipid produced, measured post-optimization, in conjunction with the 
growth curves. 
 Detailed extraction methods were developed for cholesterol and biosurfactant 
from free and encapsulated bacteria systems.  Simple extraction by use of (2:1, v/v) 
chloroform:methanol mixture resulted in biphasic separation through which cholesterol 
and biosurfactant were chemically separated and subsequently quantified using 
colorimetric methods.  By overcoming the challenge of the hydrophobicity of cholesterol 
characterization in aqueous media, the colorimetric quantification of cholesterol was 
made possible.  
It was empirically shown that there was no significant difference in cholesterol 
degradation rate as cell number was varied.  It was also empirically shown that cell 
number did not have a significant effect on cholesterol degradation rate for immobilized 
bacteria.  It was shown that the highest cholesterol degradation rate was obtained using 
lag phase bacteria immobilized by inkjet bioprinting. 
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8.2 Future Work  
A recommended future step for this research study would be to increase the 
sampling frequency to between 0 and 2 days in order to obtain a better understanding of 
the cholesterol degradation profile.  Furthermore, the study could be advanced through 
the genetic engineering of the bacterium in order to accelerate the cholesterol degradation 
rate by way of transfecting mammalian stem cells. 
Another suggested area of study would be the examination of interaction(s) 
between cholesterol and biosurfactant in order to confirm the presence of co-transport 
mechanisms.  Mathematical models could then be derived for co-transport mechanisms of 
various substances by biosurfactants.   
Also, the use of more sensitive measurement methodologies should be considered 
to obtain more accurate metabolite degradation rates.  One such example would be to 
quantify the amount of 4-cholesten-3-one using gas chromatography and mass 
spectrometry (GC-MS) techniques in order to confirm the extent of cholesterol 
conversion. 
 
 
 
 
 
 
 
 
 
 !
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10.0 APPENDIX 
10.1 APPENDIX A: DOE DATA 
 
Figure 38. Main effects plot for means for bacteria growth for t = 24 h.!
 
Figure 39. Main effects plot for signal-to-noise ratios for t = 24 h. 
!"#!
 
 
 
Figure 40. Main effects plot for means for bacteria growth for t = 48 h. 
 
 
 
Figure 41. Main effects plot for signal-to-noise ratios for bacteria growth for t = 48 h. 
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Figure 42. Main effects plot for means for glycolipid biosurfactant for t = 24 h. 
 
 
 
Figure 43. Main effects plot for signal-to-noise ratios for glycolipid biosurfactant for t = 
24 h!"
!"#!
Table 18. DOE raw data for biosurfactant mass and bacteria growth at t = 48h. 
Experiment No. Mass of Biosurfactant in mg (t = 48 h) 
Bacteria Growth 
in %T 
(t = 48 h) 
1 10.81 98.25 
2 22.51 91.78 
3 34.53 71.73 
4 26.80 64.07 
5 23.03 66.47 
6 25.28 84.11 
7 19.35 92.63 
8 16.85 88.17 
9 27.90 90.61 
10 17.09 86.89 
11 26.71 82.49 
12 16.21 97.07 
13 22.69 92.82 
14 26.31 84.74 
15 21.74 91.26 
16 23.28 70.94 
1 10.34 99.77 
2 23.06 93.87 
3 29.41 72.75 
4 25.53 67.73 
5 21.38 67.94 
6 24.66 87.71 
7 19.83 95.05 
8 24.01 90.94 
9 30.64 93.34 
10 16.40 87.08 
11 25.05 85.24 
12 17.22 96.45 
13 26.44 97.11 
14 25.81 87.18 
15 22.25 94.51 
16 24.39 70.88 
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10.2 APPENDIX B: CHOLESTEROL DEGRADATION PROFILES !
 
Figure 44. Cholesterol profile of free bacteria with medium cell count. 
 
 
Figure 45. Cholesterol profile of free bacteria with high cell count. 
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Figure 46. Cholesterol profile of atomized bacteria with medium cell count. 
 
 
 
 
Figure 47. Cholesterol profile of atomized bacteria with high cell count. 
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